Business
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
HOUSTON, May 12, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended March 31, 2026 and provides a corporate update.
About this update from Coya Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/4f403f3932e3607895047c9ca1730152"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9NN2BMZ96chBHQUtlprkMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/4f403f3932e3607895047c9ca1730152","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/UFhe8nTBjHGV_RCB0sAwzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/4f403f3932e3607895047c9ca1730152","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/bCkjGZXfVpgfZxuTP3M_7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/4f403f3932e3607895047c9ca1730152","width":1024,"height":512}},"lazy":false},{"type":"text","content":"HOUSTON, May 12, 2026--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended March 31, 2026 and provides a corporate update.","length":376,"tagName":"p"},{"type":"text","content":""We are off to a strong start in 2026, building on the clinical and scientific progress achieved last year," said Arun Swaminathan, Ph.D., Chief Executive Officer of Coya. "The ALSTARS trial is now in full recruitment mode, and we maintain our guidance for a 1Q 2027 topline readout. With a solid foundation and balance sheet in place we are well positioned to deliver on our priorities for 2026."","length":417,"tagName":"p"},{"type":"text","content":"Recent Corporate Highlights","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"FDA granted Fast Track Designation to COYA 302 for the treatment of ALS on May 11, 2026. Fast Track Designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and address unmet medical needs.","length":249,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced U.S. FDA acceptance of Investigation New Drug (IND) Application ...